A modified zinc acetate gel, a potential nonantiretroviral microbicide, is safe and effective against simian-human immunodeficiency virus and herpes simplex virus 2 infection in vivo

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 8, 2013, Pages 4001-4009

  Kenney, Jessica ^a   Rodríguez, Aixa ^a   Kizima, Larisa ^a   Seidor, Samantha ^a   Menon, Radhika ^a   Jean Pierre, Ninochka ^a   Pugach, Pavel ^a   Levendosky, Keith ^a   Derby, Nina ^a   Gettie, Agegnehu ^b   Blanchard, James ^c   Piatak, Michael ^d   Lifson, Jeffrey D ^d   Paglini, Gabriela ^e   Zydowsky, Thomas M ^a   Robbiani, Melissa ^a   Fernández Romero, José A ^a,e  

^a POPULATION COUNCIL   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^d SAIC FREDERICK INC   (United States)

^e FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CARRAGEENAN; MICROBICIDE; ZINC ACETATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANDIDA ALBICANS; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GEL; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; INFECTION SENSITIVITY; LACTOBACILLUS; LACTOBACILLUS CRISPATUS; LACTOBACILLUS JENSENII; MACACA; MOUSE; NONHUMAN; OSMOLALITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHEAR RATE; SIMIAN VIRUS; VIREMIA; VIRUS LOAD; VIRUS TRANSMISSION; VISCOSITY;

EID: 84880293565     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00796-13     Document Type: Article

References (63)

1. Celum C, Baeten JM. 2012. Antiretroviral-based HIV-1 prevention: antiretroviral treatment and pre-exposure prophylaxis. Antivir. Ther. 17: 1483-1493.
2. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329:1168-1174.
3. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. 2012. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS 26:F13-F19.
4. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malahleha M, Owino F, Manongi R, Onyango J, Temu L, Monedi MC, Mak'Oketch P, Makanda M, Reblin I, Makatu SE, Saylor L, Kiernan H, Kirkendale S, Wong C, Grant R, Kashuba A, Nanda K, Mandala J, Fransen K, Deese J, Crucitti T, Mastro TD, Taylor D. 2012. Preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 367:411-422.
5. Romano JW, Robbiani M, Doncel GF, Moench T. 2012. Non-specific microbicide product development: then and now. Curr. HIV Res. 10:9-18.
6. Kenney J, Aravantinou M, Singer R, Hsu M, Rodriguez A, Kizima L, Abraham CJ, Menon R, Seidor S, Chudolij A, Gettie A, Blanchard J, Lifson JD, Piatak M, Jr, Fernández-Romero JA, Zydowsky TM, Robbiani M. 2011. An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques. PLoS One 6:e15835. doi:10.1371/journal.pone.0015835.
7. Fernández-Romero JA, Abraham CJ, Rodriguez A, Kizima L, Jean-Pierre N, Menon R, Begay O, Seidor S, Ford BE, Gil PI, Peters J, Katz D, Robbiani M, Zydowsky TM. 2012. Zinc acetate/carrageenan gels exhibit potent activity in vivo against high-dose herpes simplex virus 2 vaginal and rectal challenge. Antimicrob. Agents Chemother. 56:358-368.
8. Ashley R. 1995. Chapter 22: herpes simplex viruses, p. 383. In Schmidt NJ, Emmons RW (ed) Diagnostic procedures for viral, rickettsial, and chlamydial infections, 7th ed. American Public Health Association, Washington, D. C.
9. Begay O, Jean-Pierre N, Abraham CJ, Chudolij A, Seidor S, Rodriguez A, Ford BE, Henderson M, Katz D, Zydowsky T, Robbiani M, Fernández-Romero JA. 2011. Identification of personal lubricants that can cause rectal epithelial cell damage and enhance HIV type 1 replication in vitro. AIDS Res. Hum. Retroviruses 27:1019-1024.
10. Moncla BJ, Pryke K, Rohan LC, Yang H. 2012. Testing of viscous anti-HIV microbicides using Lactobacillus. J. Microbiol. Methods 88: 292-296.
11. Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP, Cost M, Huang Y, Gai F, Billitto N, Lynam JD, Pryke K, Graebing P, Hopkins N, Rooney JF, Friend D, Dezzutti CS. 2010. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One 5:e9310. doi:10 .1371/journal.pone. 0009310.
12. National Research Council. 2010. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, D. C.
13. U.S. Department of Agriculture. 2001. Code of Federal Regulations, Animal Welfare Act and Regulation chapter 1, subchapter A: animals and animal products. U.S. Department of Agriculture, Beltsville, M. D.
14. Singer R, Derby N, Rodriguez A, Kizima L, Kenney J, Aravantinou M, Chudolij A, Gettie A, Blanchard J, Lifson JD, Piatak M, Jr, Fernández- Romero JA, Zydowsky TM, Robbiani M. 2011. The nonnucleoside reverse transcriptase inhibitor MIV-150 in carrageenan gel prevents rectal transmission of simian/human immunodeficiency virus infection in macaques. J. Virol. 85:5504-5512.
15. Cline AN, Bess JW, Piatak M, Jr, Lifson JD. 2005. Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J. Med. Primatol. 34:303-312.
16. Smith SM, Holland B, Russo C, Dailey PJ, Marx PA, Connor RI. 1999. Retrospective analysis of viral load and SIV antibody responses in rhesus macaques infected with pathogenic SIV: predictive value for disease progression. AIDS Res. Hum. Retroviruses 15:1691-1701.
17. García-Lerma JG, Cong ME, Mitchell J, Youngpairoj AS, Zheng Q, Masciotra S, Martin A, Kuklenyik Z, Holder A, Lipscomb J, Pau CP, Barr JR, Hanson DL, Otten R, Paxton L, Folks TM, Heneine W. 2010. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci. Transl. Med. 2:14ra4. doi:10.1126/scitranslmed .3000391.
18. Smith LM, Hensley LE, Geisbert TW, Johnson J, Stossel A, Honko A, Yen JY, Geisbert J, Paragas J, Fritz E, Olinger G, Young HA, Rubins KH, Karp CL. 2013. Interferon-beta therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J. Infect. Dis. [Epub ahead of print.] doi:10.1093/infdis/jis921.
19. Crostarosa F, Aravantinou M, Akpogheneta OJ, Jasny E, Shaw A, Kenney J, Piatak M, Lifson JD, Teitelbaum A, Hu L, Chudolij A, Zydowsky TM, Blanchard J, Gettie A, Robbiani M. 2009. A macaque model to study vaginal HSV-2/immunodeficiency virus co-infection and the impact of HSV-2 on microbicide efficacy. PLoS One 4:e8060. doi:10 .1371/journal.pone.0008060.
20. Kenney J, Singer R, Derby N, Aravantinou M, Abraham CJ, Menon R, Seidor S, Zhang S, Gettie A, Blanchard J, Piatak M, Jr, Lifson JD, Fernández- Romero JA, Zydowsky TM, Robbiani M. 2012. A single dose of a MIV-150/Zinc acetate gel provides 24 h of protection against vaginal simian human immunodeficiency virus reverse transcriptase infection, with more limited protection rectally 8-24 h after gel use. AIDS Res. Hum. Retroviruses 28:1476-1484.
21. Singer R, Mawson P, Derby N, Rodriguez A, Kizima L, Menon R, Goldman D, Kenney J, Aravantinou M, Seidor S, Gettie A, Blanchard J, Piatak M, Jr, Lifson JD, Fernández-Romero JA, Robbiani M, Zydowsky TM. 2012. An intravaginal ring that releases the NNRTI MIV-150 reduces SHIV transmission in macaques. Sci. Transl. Med. 4:150ra23. doi:10.1126/scitranslmed.3003936.
22. Turville SG, Aravantinou M, Miller T, Kenney J, Teitelbaum A, Hu L, Chudolij A, Zydowsky TM, Piatak M, Jr, Bess JW, Jr, Lifson JD, Blanchard J, Gettie A, Robbiani M. 2008. Efficacy of Carraguard-based microbicides in vivo despite variable in vitro activity. PLoS One 3:e3162. doi:10.1371/journal.pone. 0003162.
23. Chateau M, Swanson MD, Garcia JV. 2013. Inefficient vaginal transmission of tenofovir-resistant HIV-1. J. Virol. 87:1274-1277.
24. Hurt CB, Eron JJ, Jr, Cohen MS. 2011. Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin. Infect. Dis. 53: 1265-1270.
25. Cummins JE, Jr, Guarner J, Flowers L, Guenthner PC, Bartlett J, Morken T, Grohskopf LA, Paxton L, Dezzutti CS. 2007. Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture. Antimicrob. Agents Chemother. 51:1770-1779.
26. Fernández-Romero JA, Thorn M, Turville SG, Titchen K, Sudol K, Li J, Miller T, Robbiani M, Maguire RA, Buckheit RW, Jr, Hartman TL, Phillips DM. 2007. Carrageenan/MIV-150 (PC-815), a combination microbicide. Sex. Transm. Dis. 34:9-14.
27. Kilmarx PH, Blanchard K, Chaikummao S, Friedland BA, Srivirojana N, Connolly C, Witwatwongwana P, Supawitkul S, Mock PA, Chaowanachan T, Tappero J. 2008. A randomized, placebo-controlled trial to assess the safety and acceptability of use of carraguard vaginal gel by heterosexual couples in Thailand. Sex. Transm. Dis. 35:226-232.
28. Kilmarx PH, van de Wijgert JH, Chaikummao S, Jones HE, Limpakarnjanarat K, Friedland BA, Karon JM, Manopaiboon C, Srivirojana N, Yanpaisarn S, Supawitkul S, Young NL, Mock PA, Blanchard K, Mastro TD. 2006. Safety and acceptability of the candidate microbicide Carraguard in Thai women: findings from a phase II clinical trial. J. Acquir. Immune Defic. Syndr. 43:327-334.
29. Martin S, Blanchard K, Manopaiboon C, Chaikummao S, Schaffer K, Friedland B, Kilmarx PH. 2010. Carraguard acceptability among men and women in a couples study in Thailand. J. Womens Health (Larchmt) 19:1561-1567.
30. McLean CA, van de Wijgert JH, Jones HE, Karon JM, McNicoll JM, Whitehead SJ, Braunstein S, Achalapong J, Chaikummao S, Tappero JW, Markowitz LE, Kilmarx PH. 2010. HIV genital shedding and safety of Carraguard use by HIV-infected women: a crossover trial in Thailand. AIDS 24:717-722.
31. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, Govender S, De Kock A, Cassim N, Palanee T, Dozier G, Maguire R, Lahteenmaki P. 2008. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372:1977-1987.
32. Whitehead SJ, Kilmarx PH, Blanchard K, Manopaiboon C, Chaikummao S, Friedland B, Achalapong J, Wankrairoj M, Mock P, Thanprasertsuk S, Tappero JW. 2006. Acceptability of Carraguard vaginal gel use among Thai couples. AIDS 20:2141-2148.
33. Pirrone V, Passic S, Wigdahl B, Krebs FC. 2012. Application and removal of polyanionic microbicide compounds enhances subsequent infection by HIV-1. Virol. J. 9:33. doi:10.1186/1743-422X-9-33.
34. Buck CB, Thompson CD, Roberts JN, Muller M, Lowy DR, Schiller JT. 2006. Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog. 2:e69. doi:10.1371/journal.ppat.0020069.
35. Marais D, Gawarecki D, Allan B, Ahmed K, Altini L, Cassim N, Gopolang F, Hoffman M, Ramjee G, Williamson AL. 2011. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antivir. Ther. 16: 1219-1226.
36. Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, Choyke PL, Lowy DR, Schiller JT. 2007. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat. Med. 13:857-861.
37. Fenstermacher KJ, DeStefano JJ. 2011. Mechanism of HIV reverse transcriptase inhibition by zinc: formation of a highly stable enzyme-(primertemplate) complex with profoundly diminished catalytic activity. J. Biol. Chem. 286:40433-40442.
38. Mocchegiani, E., Muzzioli, M. 2000. Therapeutic application of zinc in human immunodeficiency virus against opportunistic infections. J. Nutr. 130:1424S-1431S.
39. Shankar, A. H., Prasad, A. S. 1998. Zinc and immune function: the biological basis of altered resistance to infection. Am. J. Clin. Nutr. 68: 447S-463S.
40. Hirano T, Murakami M, Fukada T, Nishida K, Yamasaki S, Suzuki T. 2008. Roles of zinc and zinc signaling in immunity: zinc as an intracellular signaling molecule. Adv. Immunol. 97:149-176.
41. Rink L, Gabriel P. 2000. Zinc and the immune system. Proc. Nutr. Soc. 59:541-552.
42. Arens M, Travis S. 2000. Zinc salts inactivate clinical isolates of herpes simplex virus in vitro. J. Clin. Microbiol. 38:1758-1762.
43. Kümel G, Schrader S, Zentgraf H, Daus H, Brendel M. 1990. The mechanism of the antiherpetic activity of zinc sulphate. J. Gen. Virol. 71:2989-2997.
44. Andrews BJ, Mylvaganam H, Yule A. 1994. Sensitivity of Trichomonas vaginalis, Tritrichomonas foetus and Giardia intestinalis to bacitracin and its zinc salt in vitro. Trans. R. Soc. Trop. Med. Hyg. 88:704-706.
45. Prasad AS, Beck FW, Bao B, Snell D, Fitzgerald JT. 2008. Duration and severity of symptoms and levels of plasma interleukin-1 receptor antagonist, soluble tumor necrosis factor receptor, and adhesion molecules in patients with common cold treated with zinc acetate. J. Infect. Dis. 197: 795-802.
46. Suara RO, Crowe JE, Jr. 2004. Effect of zinc salts on respiratory syncytial virus replication. Antimicrob. Agents Chemother. 48:783-790.
47. Chvapil M, Chvapil TA, Owen JA, Kantor M, Ulreich JB, Eskelson C. 1979. Reaction of vaginal tissue of rabbits to inserted sponges made of various materials. J. Biomed. Mater Res. 13:1-13.
48. Fahim MS, Wang M. 1996. Zinc acetate and lyophilized aloe barbadensis as vaginal contraceptive. Contraception. 53:231-236.
49. Alexander TH, Davidson TM. 2006. Intranasal zinc and anosmia: the zinc-induced anosmia syndrome. Laryngoscope 116:217-220.
50. Bourne N, Stegall R, Montano R, Meador M, Stanberry LR, Milligan GN. 2005. Efficacy and toxicity of zinc salts as candidate topical microbicides against vaginal herpes simplex virus type 2 infection. Antimicrob. Agents Chemother. 49:1181-1183.
51. Trumbo P, Yates AA, Schlicker S, Poos M. 2001. Dietary reference intakes: vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. J. Am. Diet Assoc. 101:294-301.
52. Rupp R, Rosenthal SL, Stanberry LR. 2007. VivaGel (SPL7013 Gel): a candidate dendrimer-microbicide for the prevention of HIV and HSV infection. Int. J. Nanomedicine 2:561-566.
53. Talwar GP, Raghuvanshi P, Mishra R, Banerjee U, Rattan A, Whaley KJ, Zeitlin L, Achilles SL, Barré-Sinoussi F, David A, Doncel GF. 2000. Polyherbal formulations with wide spectrum antimicrobial activity against reproductive tract infections and sexually transmitted pathogens. Am. J. Reprod. Immunol. 43:144-151.
54. Emau P, Tian B, O'Keefe BR, Mori T, McMahon JB, Palmer KE, Jiang Y, Bekele G, Tsai CC. 2007. Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide. J. Med. Primatol. 36:244-253.
55. O'Keefe BR, Vojdani F, Buffa V, Shattock RJ, Montefiori DC, Bakke J, Mirsalis J, d'Andrea AL, Hume SD, Bratcher B, Saucedo CJ, McMahon JB, Pogue GP, Palmer KE. 2009. Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc. Natl. Acad. Sci. U. S. A. 106:6099-6104.
56. Moore MD, Cookson J, Coventry VK, Sproat B, Rabe L, Cranston RD, McGowan I, James W. 2011. Protection of HIV neutralizing aptamers against rectal and vaginal nucleases: implications for RNA-based therapeutics. J. Biol. Chem. 286:2526-2535.
57. Wheeler LA, Trifonova R, Vrbanac V, Basar E, McKernan S, Xu Z, Seung E, Deruaz M, Dudek T, Einarsson JI, Yang L, Allen TM, Luster AD, Tager AM, Dykxhoorn DM, Lieberman J. 2011. Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J. Clin. Invest. 121:2401-2412.
58. Brinckmann S, da Costa K, van Gils MJ, Hallengard D, Klein K, Madeira L, Mainetti L, Palma P, Raue K, Reinhart D, Reudelsterz M, Ruffin N, Seifried J, Schäfer K, Sheik-Khalil E, Sköld A, Uchtenhagen H, Vabret N, Ziglio S, Scarlatti G, Shattock R, Wahren B, Gotch F. 2011. Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010. J. Transl. Med. 9:40. doi:10.1186/1479-5876-9-40.
59. Gong E, Matthews B, McCarthy T, Chu J, Holan G, Raff J, Sacks S. 2005. Evaluation of dendrimer SPL7013, a lead microbicide candidate against herpes simplex viruses. Antiviral Res. 68:139-146.
60. Jiang YH, Emau P, Cairns JS, Flanary L, Morton WR, McCarthy TD, Tsai CC. 2005. SPL7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV89.6P in macaques. AIDS Res. Hum. Retroviruses 21:207-213.
61. Price CF, Tyssen D, Sonza S, Davie A, Evans S, Lewis GR, Xia S, Spelman T, Hodsman P, Moench TR, Humberstone A, Paull JR, Tachedjian G. 2011. SPL7013 Gel (VivaGel(R)) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans. PLoS One 6:e24095. doi:10.1371/journal.pone. 0024095.
62. Tyssen D, Henderson SA, Johnson A, Sterjovski J, Moore K, La J, Zanin M, Sonza S, Karellas P, Giannis MP, Krippner G, Wesselingh S, Mc-Carthy T, Gorry PR, Ramsland PA, Cone R, Paull JR, Lewis GR, Tachedjian G. 2010. Structure activity relationship of dendrimer microbicides with dual action antiviral activity. PLoS One 5:e12309. doi:10.1371/journal.pone.0012309.
63. Bernstein DI, Stanberry LR, Sacks S, Ayisi NK, Gong YH, Ireland J, Mumper RJ, Holan G, Matthews B, McCarthy T, Bourne N. 2003. Evaluations of unformulated and formulated dendrimer-based microbicide candidates in mouse and guinea pig models of genital herpes. Antimicrob. Agents Chemother. 47:3784-3788.